...
In diesem Abschnitt
Für Betroffene & Angehörige

Med. Fachperson

Für Betroffene & Angehörige

Alles auf einen “Klick”

    In diesem Abschnit

    Für welche Indikationen ist Reagila® zugelassen?

    Referenzen

    1. Fachinformation Reagila®. Stand der Information September 2023, www.swissmedicinfo.ch.
    2. www.ema.europa.eu
    3. www.fda.gov
    4. Hasler G et al., Behandlungsempfehlungen der Schweizerischen Gesellschaft für Bipolare Störungen (SGBS). Bipolare Störungen: Update 2019. smf 2019;19 (33-34): 537-546. https://doi.org/10.4414/smf.2019.08325, zuletzt aufgerufen am 14.02.2024.

    Was ist der Wirkmechanismus von Reagila®? Wie unterscheidet es sich von anderen Antipsychotika?

    Referenzen

    1. Fachinformation Reagila®. Stand der Information September 2023, www.swissmedicinfo.ch.
    2. Stahl. Essential Pharmacology 4th edition 2013v (adaptiert).
    3. Hjorth St., The More, the Merrier…? Antipsychotic PolypharmacyTreatment Strategies in Schizophrenia From a Pharmacology Perspective. Front Psychiatry. 2021; 12: 760181.
    4. Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016; 21(2): 123–7.
    5. Stahl S. Drugs for psychosis and mood: unique actions at D3, D2 and D1 dopamine receptor subtypes. CNS Spectrums. 2017, 22:375-384. 11.
    6. Kiss B et al., Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3) / D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp.Ther. 2010; 333(1): 328-40.
    7. Durgam S et al., Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016; 176(2 3): 264-271. 
    8. Correll C et al., Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatric Disease and Treatment 2019:15 2537–2550

    Wie wirksam ist Reagila®?

    Referenzen

    1. Fachinformation Reagila®. Stand der Information September 2023, www.swissmedicinfo.ch.
    2. Durgam S et al., Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015; 76(12).
    3. Kane JM et al., Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, Phase III clinical trial. J Clin Psychopharmacol. 2015; 35(4): 367-73.
    4. Durgam S et al., An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophr Res. 2014; 152: 450-45.
    5. Marder S et al., Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II / III studies. European Neuropsychopharmacology (2019) 29, 127-136.
    6. Durgam S et al., Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016; 176(2 3): 264-271.
    7. Németh G et al., Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; 389(10074): 1103-1113.
    8. Fleischhacker W et al., The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. European Psychiatry 58 (2019) 1–9.
    9. Durgam S et al., Safety and tolerability of cariprazine in the longterm treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology. 2017; 234(2): 199–209.
    10. Cutler AJ et al., Evaluation of the long-term safety and tolerability of Cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS, Spectr. 2018; 23(1): 39-50

    Auf welcher Evidenz beruht die Aussage zur Überlegenheit von Reagila® bei Negativsymptomatik?

    Referenzen

    1. Fachinformation Reagila®. Stand der Information September 2023, www.swissmedicinfo.ch.
    2. Németh G et al., Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; 389(10074): 1103-1113.
    3. Fleischhacker W et al., The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. European Psychiatry 58 (2019) 1–9.
    4. Leucht S et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31-41.

    Welche Nebenwirkungen sind gegebenenfalls zu erwarten?

    Referenzen

    1. Fachinformation Reagila®. Stand der Information September 2023, www.swissmedicinfo.ch.
    2. Durgam S et al., Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015; 76(12).
    3. Kane JM et al., Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, Phase III clinical trial. J Clin Psychopharmacol. 2015; 35(4): 367-73.
    4. Durgam S et al., An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophr Res. 2014; 152: 450-45.
    5. Durgam S et al., Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016; 176(2 3): 264-271.
    6. Durgam S et al., Safety and tolerability of cariprazine in the longterm treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology. 2017; 234(2):199–209.
    7. Cutler AJ et al., Evaluation of the long-term safety and tolerability of Cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS, Spectr. 2018; 23(1): 39-50.

    Wie dosiert man Reagila®?

    Referenzen

    1. Fachinformation Reagila®. Stand der Information September 2023, www.swissmedicinfo.ch.
    2. Stahl S, Stahl’s Essential Psychopharmacology Prescriber’s Guide, 6th edition, Cambridge University Press, 2017.
    3. Fagiolini A, Brugnoli R, Di Sciascio G, De Filippis S, Maina G. Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opin Pharmacother. 2015 Apr;16(5):727-37.
    4. Sullivan G, Bienroth M, Jones M, Millar H, Ratna L, Taylor D. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin. 2007 Jul;23(7):1733-44.

    Ist Reagila® geeignet in der Kombination mit anderen Medikamenten?

    Referenzen

    1. Fachinformation Reagila®. Stand der Information September 2023, www.swissmedicinfo.ch.
    2. Hjorth St., The More, the Merrier…? Antipsychotic PolypharmacyTreatment Strategies in Schizophrenia From a Pharmacology Perspective. Front Psychiatry. 2021; 12: 760181.

    Weshalb sollte Reagila® bei Patienten mit Doppeldiagnose als eine Therapie der Wahl angesehen werden?

    Referenzen

    1. Fachinformation Reagila®. Stand der Information September 2023, www.swissmedicinfo.ch.
    2. Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016; 21(2): 123–7.
    3. Stahl S. Drugs for psychosis and mood: unique actions at D3, D2 and D1 dopamine receptor subtypes. CNS Spectrums. 2017, 22:375-384. 11.Stahl S. Drugs for psychosis and mood: unique actions at D3, D2 and D1 dopamine
    4. Durgam S et al., Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016; 176(2 3): 264-271. 
    5. Correll C et al., Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatric Disease and Treatment 2019:15 2537–2550.
    6. Németh G et al., Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; 389(10074): 1103-1113.
    7. Masroor A, et al. Unraveling the Association Between Schizophrenia and Substance Use Disorder-Predictors, Mechanisms and Treatment Modifications: A Systematic Review. Cureus. 2021;13(7): e16722.
    8. Lähteenvuo M, et al. Morbidity and mortality in schizophrenia with comorbid substance use disorders. Acta Psychiat Scand. 2021; 144(1):42-49.
    9. Hunt GE, et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. Drug Alcoh Dep. 2018;191:234-258.
    10. Ricci V, et al. Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: presentation of a case report. J Addict Dis. 2022;40:145–148.
    11. Rodriguez Cruz J, et al. Case report: cariprazine in a patient with schizophrenia, substance abuse, and cognitive dysfunction. Front Psychiatry. 2021;12:727666.
    12. Carmassi C, et al. Clinical experiences with cariprazine in schizophrenic patients with comorbid substance abuse. Evid based Psychiatr Care. 2019;05(Suppl. 03):11–4.
    13. Duque-Yemail JD, et al. Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series. Neuropsych Dis Treatm. 2022:18 1433–1440.
    14. Moran RA, et al. A Case Report of Treatment With Cariprazine in a Recurrent Psychosis Presumably Induced by Methamphetamine. Cureus.2023;15(10): e47135.
    15. Martinotti G et al. Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice. Curr Pharm Des. 2022;28(27):2241-2259.
    Share
    Close
    Sie verlassen nun die Webseite und werden auf eine externe Webseite weitergeleitet.
    Akzeptieren
    Abbrechen
    Showing 0 result(s).
    Please log in to see 0 more result(s).
    Seraphinite AcceleratorOptimized by Seraphinite Accelerator
    Turns on site high speed to be attractive for people and search engines.